BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21224931)

  • 21. Update on evidence for treatment with ranolazine in stable angina.
    Carbone F; Montecucco F; Mach F
    Swiss Med Wkly; 2013; 143():w13874. PubMed ID: 24163124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
    J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons.
    Peters CH; Sokolov S; Rajamani S; Ruben PC
    Br J Pharmacol; 2013 Jun; 169(3):704-16. PubMed ID: 23472826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular news.
    SoRelle R
    Circulation; 2001 Nov; 104(22):E9053-5. PubMed ID: 11723043
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of myocardial ischemia. Is ranolazine needed? For all or some patients with myocardial ischemia?
    Cocco G
    Expert Opin Pharmacother; 2012 Dec; 13(17):2429-32. PubMed ID: 23121536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ranolazine (Ranexa) for chronic stable angina.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Jun; (99):1-6. PubMed ID: 17595750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.
    Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
    Ann N Y Acad Sci; 2008 Mar; 1123():105-12. PubMed ID: 18375582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of ranolazine on cardiovascular system.
    Bonadei I; Vizzardi E; Quinzani F; Piovanelli B; Rovetta R; D'Aloia A; Cas LD
    Recent Pat Cardiovasc Drug Discov; 2011 Sep; 6(3):215-21. PubMed ID: 21867482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. At the dawn of a new era in treating angina pectoris, or just another antianginal drug? Some considerations about ranolazine.
    Bălan H
    Rom J Intern Med; 2010; 48(4):361-9. PubMed ID: 21528766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New agents for the therapy of angina pectoris].
    Meinertz T; Köster R
    Internist (Berl); 2011 Jul; 52(7):894-6, 898-900. PubMed ID: 21713611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential application of late sodium current blockade in the treatment of heart failure and atrial fibrillation.
    Doshi D; Morrow JP
    Rev Cardiovasc Med; 2009; 10 Suppl 1():S46-52. PubMed ID: 19898288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
    Scirica BM; Morrow DA; Hod H; Murphy SA; Belardinelli L; Hedgepeth CM; Molhoek P; Verheugt FW; Gersh BJ; McCabe CH; Braunwald E
    Circulation; 2007 Oct; 116(15):1647-52. PubMed ID: 17804441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Ranolazine--new treatment of chronic stable angina pectoris].
    Ahlehoff O; Hansen PR
    Ugeskr Laeger; 2009 Dec; 171(50):3705-7. PubMed ID: 20003868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expanding the understanding of the treatment of chronic angina: a 21st century approach-part II.
    Conti CR
    Clin Cardiol; 2008 Jul; 31(7):295-6. PubMed ID: 18636470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ranolazine: a new option in the management of chronic stable angina.
    Dobesh PP; Trujillo TC
    Pharmacotherapy; 2007 Dec; 27(12):1659-76. PubMed ID: 18041887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.
    Bhandari B; Subramanian L
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):35-9. PubMed ID: 18221101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ranolazine in patients with coronary artery disease.
    Scirica BM
    Expert Opin Pharmacother; 2007 Sep; 8(13):2149-57. PubMed ID: 17714067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ranolazine: a review of its use in chronic stable angina pectoris.
    Siddiqui MA; Keam SJ
    Drugs; 2006; 66(5):693-710. PubMed ID: 16620147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiarrhythmic properties of ranolazine--from bench to bedside.
    Tzeis S; Andrikopoulos G
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1733-41. PubMed ID: 22916846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
    Sossalla S; Maier LS
    Pharmacol Ther; 2012 Mar; 133(3):311-23. PubMed ID: 22133843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.